AQR Capital Management
CRBP icon

AQR Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

AQR Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,407
Closed -$196K – 3488
2025
Q2 		$196K Sell
28,407
-79,576
-74% -$578K ﹤0.01% 3051
2025
Q1 		$573K Buy
+107,983
New +$953K ﹤0.01% 2348
2024
Q4 		– Sell
-64,366
Closed -$1.33M – 2886
2024
Q3 		$1.33M Buy
+64,366
New +$3.29M ﹤0.01% 1710
2018
Q1 		– Sell
-912
Closed -$194K – 2229
2017
Q4 		$194K Sell
912
-696
-43% -$149K ﹤0.01% 2160
2017
Q3 		$345K Buy
1,608
+565
+54% +$111K ﹤0.01% 2043
2017
Q2 		$197K Buy
+1,043
New +$205K ﹤0.01% 2131

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AQR Capital Management's CRBP Position: Q3 2025 in Review

AQR Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q3 2025, closing a stake of 28,407 shares — an estimated $196K sold.

AQR Capital Management first reported a position in CRBP in Q2 2017 and held it in 6 quarters. The position peaked at $1.33M in Q3 2024. 81 funds tracked by Wall St. Rank hold CRBP as of Q3 2025.

  • AQR Capital Management reported no remaining Corbus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • AQR Capital Management sold 28,407 Corbus Pharmaceuticals shares in Q3 2025, an estimated $196K.
  • AQR Capital Management first reported a position in Corbus Pharmaceuticals in Q2 2017 and held it in 6 quarters.
  • AQR Capital Management's Corbus Pharmaceuticals position peaked at $1.33M in Q3 2024.
  • 81 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.